FI3191120T3 - Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla - Google Patents

Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla Download PDF

Info

Publication number
FI3191120T3
FI3191120T3 FIEP15767597.6T FI15767597T FI3191120T3 FI 3191120 T3 FI3191120 T3 FI 3191120T3 FI 15767597 T FI15767597 T FI 15767597T FI 3191120 T3 FI3191120 T3 FI 3191120T3
Authority
FI
Finland
Prior art keywords
secukinumab
use according
acid derivative
progression
structural damage
Prior art date
Application number
FIEP15767597.6T
Other languages
English (en)
Finnish (fi)
Inventor
Shephard Mpofu
Hanno Richards
Gregory Ligozio
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54186247&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI3191120(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of FI3191120T3 publication Critical patent/FI3191120T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Oncology (AREA)
FIEP15767597.6T 2014-09-10 2015-09-08 Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla FI3191120T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462048512P 2014-09-10 2014-09-10
PCT/IB2015/056871 WO2016038538A1 (en) 2014-09-10 2015-09-08 Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients

Publications (1)

Publication Number Publication Date
FI3191120T3 true FI3191120T3 (fi) 2024-07-10

Family

ID=54186247

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP15767597.6T FI3191120T3 (fi) 2014-09-10 2015-09-08 Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla

Country Status (22)

Country Link
US (2) US11278618B2 (enExample)
EP (2) EP3191120B1 (enExample)
JP (4) JP2017528465A (enExample)
KR (3) KR20170045240A (enExample)
CN (4) CN107073110A (enExample)
AU (2) AU2015313827C1 (enExample)
BR (1) BR112017003332A2 (enExample)
CA (1) CA2960754A1 (enExample)
DK (1) DK3191120T3 (enExample)
ES (1) ES2981697T3 (enExample)
FI (1) FI3191120T3 (enExample)
HR (1) HRP20240921T1 (enExample)
HU (1) HUE067081T2 (enExample)
LT (1) LT3191120T (enExample)
MX (1) MX2017003216A (enExample)
PL (1) PL3191120T3 (enExample)
PT (1) PT3191120T (enExample)
RS (1) RS65851B1 (enExample)
RU (1) RU2697383C2 (enExample)
SI (1) SI3191120T1 (enExample)
SM (1) SMT202400285T1 (enExample)
WO (1) WO2016038538A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3191120T3 (fi) * 2014-09-10 2024-07-10 Novartis Ag Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla
CN108350068A (zh) 2015-10-27 2018-07-31 Ucb生物制药私人有限公司 使用抗-il-17a/f抗体的治疗方法
US10676522B2 (en) * 2017-05-05 2020-06-09 Novartis Ag Methods of selectively treating asthma using IL-17 antagonists
EP3672988A1 (en) * 2017-08-23 2020-07-01 Eli Lilly and Company Treatment of genital psoriasis
AU2018361975A1 (en) * 2017-11-02 2020-05-07 Novartis Ag Method of treating tendinopathy using interleukin-17 (IL-17) antagonists
US20200385453A1 (en) * 2019-06-04 2020-12-10 Janssen Biotech, Inc. Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
KR102604172B1 (ko) 2019-12-05 2023-11-22 아주대학교산학협력단 펩타이드 또는 이의 혼합물을 유효성분으로 함유하는 베체트병 또는 류마티스 관절염 예방 또는 치료용 약학조성물
KR102394378B1 (ko) 2020-10-14 2022-05-03 한림대학교 산학협력단 피부 각질세포에서의 아릴탄화수소 수용체 억제자(AhRR) 과발현 방법
EP4305062A1 (en) 2021-03-12 2024-01-17 Janssen Biotech, Inc. Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
PL1963368T6 (pl) 2005-12-13 2021-02-08 Eli Lilly And Company Przeciwciała anty-IL-17
CA2637166A1 (en) 2006-01-31 2007-10-18 Novartis Ag Il-17 antagonistic antibodies for treating cancer
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
BRPI0813262A2 (pt) 2007-06-20 2015-04-14 Schering Corp Biomarcadores de destruição de articulação para terapia de doença inflamatória de articulação anti-il-17a
US7856118B2 (en) 2007-07-20 2010-12-21 The Procter & Gamble Company Methods for recommending a personal care product and tools therefor
CA2737636A1 (en) 2008-09-29 2010-04-01 Roche Glycart Ag Antibodies against human il17 and uses thereof
MX356279B (es) * 2010-10-08 2018-05-22 Novartis Ag Star Métodos para el tratamiento de soriasis usando antagonistas de il-17.
AU2011325134B2 (en) * 2010-11-05 2014-10-23 Novartis Ag Methods of treating rheumatoid arthritis using IL-17 antagonists
TW201307845A (zh) * 2010-12-13 2013-02-16 Novartis Ag 預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
RU2014125071A (ru) * 2011-11-21 2015-12-27 Новартис Аг Способы лечения псориатического артрита (psa) с использованием антагонистов il-17 и аллелей ответа psa или отсутствия ответа psa
CN103936854B (zh) * 2014-04-30 2016-08-17 北京精益泰翔技术发展有限公司 抗il-17a单克隆抗体及其制备与应用
FI3191120T3 (fi) * 2014-09-10 2024-07-10 Novartis Ag Il-17-antagonistien käyttö rakennevaurion etenemisen estämiseksi nivelpsoriaasipotilailla

Also Published As

Publication number Publication date
RU2017107501A3 (enExample) 2019-03-12
AU2015313827C1 (en) 2018-08-30
EP3191120B1 (en) 2024-04-10
SI3191120T1 (sl) 2024-10-30
EP4406969A3 (en) 2024-11-27
US20170281762A1 (en) 2017-10-05
RU2697383C2 (ru) 2019-08-13
AU2015313827A1 (en) 2017-02-16
JP7288927B2 (ja) 2023-06-08
JP2025024104A (ja) 2025-02-19
EP4406969A2 (en) 2024-07-31
CN113069542A (zh) 2021-07-06
RU2017107501A (ru) 2018-10-10
CN107073110A (zh) 2017-08-18
PT3191120T (pt) 2024-07-16
CN115944734A (zh) 2023-04-11
US11278618B2 (en) 2022-03-22
AU2015313827B2 (en) 2018-02-15
LT3191120T (lt) 2024-07-25
US20220313818A1 (en) 2022-10-06
KR20230170796A (ko) 2023-12-19
JP2023109973A (ja) 2023-08-08
HRP20240921T1 (hr) 2024-10-11
CN115957326A (zh) 2023-04-14
RS65851B1 (sr) 2024-09-30
ES2981697T3 (es) 2024-10-10
SMT202400285T1 (it) 2024-09-16
PL3191120T3 (pl) 2024-08-26
JP2021152021A (ja) 2021-09-30
JP7591092B2 (ja) 2024-11-27
AU2018201410A1 (en) 2018-03-22
CA2960754A1 (en) 2016-03-17
KR20260087713A (ko) 2026-06-11
WO2016038538A1 (en) 2016-03-17
KR20170045240A (ko) 2017-04-26
HUE067081T2 (hu) 2024-09-28
MX2017003216A (es) 2017-05-23
BR112017003332A2 (pt) 2017-11-28
EP3191120A1 (en) 2017-07-19
DK3191120T3 (da) 2024-07-15
JP2017528465A (ja) 2017-09-28

Similar Documents

Publication Publication Date Title
HRP20240921T1 (hr) Upotreba antagonista il-17 za inhibiciju napredovanja strukturnog oštećenja kod bolesnika s psorijatičnim artritisom
EP3554342C0 (en) TREATMENT OF GASTROINTESTINAL TRACT DISEASE WITH A TNF INHIBITOR
DK3331864T3 (da) 1,3,4-Oxadiazolderivat-forbindelser som histon-deacetylase-6-hæmmer, og den farmaceutiske sammensætning omfattende disse
FI3328843T3 (fi) 1,3,4-oksadiatsolisulfonamidijohdannaisyhdisteitä histonideasetylaasi-6:n inhibiittoreina ja samaa käsittävä farmaseuttinen koostumus
EP2734500A4 (en) SELECTIVE HISTONDEACETYLASE-6 INHIBITORS FOR THE TREATMENT OF BONE DISORDERS
CL2008001868A1 (es) Compuestos derivados de n-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas; composicion farmaceutica que comprende a dicho compuesto; y uso para el tratamiento de enfermedades inflamatorias del intestino, enfermedad alergica
JP2016533817A5 (enExample)
JOP20200230B1 (ar) ناهضات ppar (مستقبل ناشر بيروكسيزوم منشط)، ومركبات، ومكونات أدوية، وطرق استعمالها
JP2019521116A5 (enExample)
JP2019532634A5 (enExample)
IL300130B2 (en) New combinations for antigen-based therapy
NZ602029A (en) Use of meloxicam for the long-term treatment of kidney disorders in cats
HRP20260324T1 (hr) Guselkumab za upotrebu u liječenju crohnove bolesti uz režim doziranja
EA201491039A1 (ru) Комбинации диацереина и нестероидных противовоспалительных лекарственных средств
MX2021008432A (es) Composiciones farmaceuticas y usos dirigidos a los trastornos del almacenamiento lisosomal.
EP3177357C0 (fr) Dispositif pour l'introduction d'une canule à bout arrondi sous la peau d'un patient et kit
HRP20241716T1 (hr) Postupci liječenja promjena u ponašanju
RU2016148183A (ru) (s)-пирлиндол и его фармацевтические приемлемые соли для применения в медицине
RU2018126158A (ru) Применение триацетил-3-гидроксифениладенозина для получения фармацевтического лекарственного средства для предупреждения или лечения неалкогольной жировой болезни печени
CR20150646A (es) 4-(5-(4-clorofenil)-2-(2-ciclopropilacetil)-1,4-dimetil-1h-pirrol-3-il)bencenosulfonamida como modulador de nachr alfa
HUE042932T2 (hu) Koleszterinészter-transzferprotein (CETP) inhibitor és az említett inhibitort tartalmazó gyógyászati készítmény szív- és érrendszeri betegségek kezelésében vagy megelõzésében való alkalmazásra
JP2016520556A5 (enExample)
RU2016148182A (ru) (r)-пирлиндол и его фармацевтически приемлемые соли для применения в медицине
AR063228A1 (es) Antinflamatorios no esteroideos contra la tos
RU2015136958A (ru) 2-арил-2, 4-дигидрокси-2, 5-дигидро-3-гетерил-5-оксо-1н-пиррол-1-ил-4-метилбелзолсульфаниламиды, обладающие анальгетической активностью